Detroit Receiving Hospital

About: Detroit Receiving Hospital is a healthcare organization based out in Detroit, Michigan, United States. It is known for research contribution in the topics: Vancomycin & Population. The organization has 877 authors who have published 850 publications receiving 37202 citations. The organization is also known as: Detroit General.

Simple method of applying pressure to skin grafts of neck with foam dressing and staples.

Abstract: Pressure applied over a skin graft prevents formation of hematoma and shearing of the graft. Most of the methods used to obtain adequate pressure are often cumbersome to apply and time-consuming. This report describes a quick and simple method for fixing and applying pressure over skin graft with foam dressing and staples.

Teicoplanin pharmacodynamics in reference to the accessory gene regulator (agr) in Staphylococcus aureus using an in vitro pharmacodynamic model

Abstract: Objectives: The accessory gene regulator (agr) has been identified as playing a role in the expression of reduced glycopeptide susceptibility in Staphylococcus aureus. Previous studies indicate that strains with agr dysfunctional group II polymorphism have a higher propensity for reduced vancomycin activity. We investigated this relationship in agr groups I‐IV using another glycopeptide, teicoplanin, in an in vitro pharmacodynamic model. Methods: Teicoplanin doses ranging from 1.88 to 30 mg/kg daily (fAUC/MIC 26.1‐380.7) were simulated and evaluated for activity and the development of reduced susceptibility over 72 h.

In Vitro Synergy of Colistin in Combination with Meropenem or Tigecycline against Carbapenem-Resistant Acinetobacter baumannii.

Abstract: Acinetobacter baumannii is currently classified as one of six pathogens that contribute to increased patient mortality. Thus, exploratory studies navigating alternative treatment strategies are of supreme interest. Herein, we completed minimum inhibitory concentration (MIC) testing, and time-kill analyses (TKA) on 50 carbapenem-resistant Acinetobacterbaumannii isolates including 28 colistin-resistant isolates. Upon testing of MEM or TGC in the presence of sub-inhibitory COL against the 50 isolates, there was a median 2-fold reduction in MEM and TGC MICs. In the TKAs, the COL+MEM combination was synergistic in 45 (90%) isolates and bactericidal in 43 (86%) isolates at 24 hours, whereas the COL+TGC combination TKAs demonstrated synergy in 32 (64%) isolates and bactericidal activity was shown in 28 (56%) isolates. Additionally, sulbactam (SUL) and TGC were added to the COL+MEM dual therapy regimen to assess the possible utility of a triple therapy regimen against five non-responsive isolates. The COL+MEM+SUL and COL+MEM+TGC regimens effectively restored synergy in (5/5) 100% of the isolates. The results of this study demonstrate the potential utility of COL combinations in the treatment of carbapenem-resistant isolates.

New cholesterol reagent.

Abstract: A study was carried out on a new cholesterol reagent which was reported to be a saturated solution of ferrous sulfate in glacial acetic acid. This solution was shown to be unstable and it is suggested that the reactive state of the metal involved is that of the more stable trivalent ferric iron.